=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Bruce Merchant, MD, PhD
Nascent Biotech, Inc.
(b) (4) MA 1

Page 4

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Pritumumab comply with
each applicable requirement of the FD&C Act and FDA implementing regulations.

Sincerely,

{See appended electronic signature page}
Emily M. Dvorsky, PharmD
Regulatory Review Officer
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

{See appended electronic signature page}
Susannah O'Donnell, MPH, RAC
Team Leader
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

Reference ID: 4514664
